The bonds will come due 2025. Sosei Heptares will use the funds to pursue growth initiatives. Those initiatives include a potential acquisition, investments in its drug discovery platform, and licensing late-stage clinical assets to build its presence in the Japanese market.
Sosei has a pipeline of candidates in gastroenterology, immuno-oncology, inflammation and other rare/specialty indications.
More articles on surgery centers:
Hybrid ASC is up and running with 43 cardiac partners: 6 things to know
Florida ASC closes real-estate sale-leaseback transaction: 4 details
Ohio health system acquires surgery center for $21M
